The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.
Open accessAbstract
We have investigated human gliomas that amplify and rearrange the epidermal growth factor receptor gene, with generation of an in-frame deletion mutation of 802 nucleotides in the external domain. This in-frame deletion mutation generates a local amino acid sequence at the fusion junction of what normally were distant polypeptide sequences in the intact epidermal growth factor receptor. This 14-amino acid peptide was chemically synthesized, coupled to keyhole limpet hemocyanin, and used as an immunogen in rabbits. The elicited antibody reacted specifically with the fusion peptide in ELISA. The anti-fusion junction peptide antibody was purified by passage of the antiserum over a peptide affinity column with acidic elution. The purified antibody selectively bound the glioma deletion mutant as compared to the intact epidermal growth factor receptor as assessed by immunocytochemistry, immunofluorescence, immunoprecipitation with gel electrophoresis, and binding experiments using radioiodinated antibody. These data indicate that it is feasible to generate site-specific anti-peptide antibodies that are highly selective for mutant proteins in human tumors. The anti-peptide antibody described here, and other mutation site-specific antibodies, should be ideal candidates for tumor immunoimaging and immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849
Self-citationKawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Expression of epidermal growth factor receptors in human brain tumors.
Libermann, T. A., Razon, N., Bartal, A. D., Yarden, Y., Schlessinger, J., & Soreq, H. (1984) · PubMed · Cited by 473
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.
Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J. M., Polikoff, J., & SATO, G. H. (1983) · PubMed · Cited by 458
Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
Cited by
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
“Gibbs(34), Joe Gray(28), Raju Kucherlapati(22), Marc Ladanyi(27), Eric Lander(4,60,61), Richard M.”
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Malignant glioma: genetics and biology of a grave matter
Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., & DePinho, R. A. (2001) · Genes & Development · doi:10.1101/gad.891601 · Cited by 1,229
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227
“Moreover, many laboratories embarked on a massive search for EGFR mutations in human cancers and several deletions and point mutations were described that result in increased catalytic tyrosine-kinase activity of the recepto”
BackgroundA mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
Structural alterations of the epidermal growth factor receptor gene in human gliomas.
Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., & Vogelstein, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2965 · Cited by 853
Self-citationSampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
Self-citationBrain immunology and immunotherapy in brain tumours
Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0224-7 · Cited by 722
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
Nathanson, D. A., Gini, B., Mottahedeh, J., Visnyei, K., Koga, T., Gomez, G., Eskin, A., Hwang, K., Wang, J., Masui, K., et al. (2014) · Science · doi:10.1126/science.1241328 · Cited by 695
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Ekstrand, A. J., Sugawa, N., James, C. D., & Collins, V. P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4309 · Cited by 602
Huang, H.-J. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X.-D., Huang, C.-M., Gill, G. N., Wiley, H. S., & Cavenee, W. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.5.2927 · Cited by 595
Sugawa, N., Ekstrand, A. J., James, C. D., & Collins, V. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8602 · Cited by 594
Current and future strategies for treatment of glioma
Bush, N. A. O., Chang, S. M., & Berger, M. S. (2017) · Neurosurgical Review · doi:10.1007/s10143-016-0709-8 · Cited by 577
Rude Voldborg, B., Damstrup, L., Spang-Thomsen, M., & Skovgaard Poulsen, H. (1997) · Annals of Oncology · doi:10.1023/a:1008209720526 · Cited by 528
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802997-8.00023-2 · Cited by 472
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
Schuster, J., Lai, R. K., Recht, L. D., Reardon, D. A., Paleologos, N. A., Groves, M. D., Mrugala, M. M., Jensen, R., Baehring, J. M., Sloan, A., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou348 · Cited by 422
Self-citationHadjipanayis, C. G., Machaidze, R., Kaluzova, M., Wang, L., Schuette, A. J., Chen, H., Wu, X., & Mao, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1022 · Cited by 419
Goff, S. L., Morgan, R. A., Yang, J. C., Sherry, R. M., Robbins, P. F., Restifo, N. P., Feldman, S. A., Lu, Y.-C., Lu, L., Zheng, Z., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000260 · Cited by 377
The epidermal growth factor receptor variant III (EGFR v III): where wild things are altered
Gan, H. K., Cvrljevic, A. N., & Johns, T. G. (2013) · The FEBS Journal · doi:10.1111/febs.12393 · Cited by 370
Sampson, J. H., Aldape, K. D., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq157 · Cited by 370
Self-citationThe type 1 (EGFR-related) family of growth factor receptors and their ligands
Prigent, S. A., & Lemoine, N. R. (1992) · Progress in Growth Factor Research · doi:10.1016/0955-2235(92)90002-y · Cited by 369
Spector, N. L., Xia, W., Burris, H., Hurwitz, H., Dees, E. C., Dowlati, A., O'Neil, B., Overmoyer, B., Marcom, P. K., Blackwell, K. L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.157 · Cited by 362
Fucoidan and Cancer: A Multifunctional Molecule with Anti-Tumor Potential
Atashrazm, F., Lowenthal, R., Woods, G., Holloway, A., & Dickinson, J. (2015) · Marine Drugs · doi:10.3390/md13042327 · Cited by 358
Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., Victor, A., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 340
EGF mutant receptor vIII as a molecular target in cancer therapy.
Kuan, C. T., Wikstrand, C. J., & Bigner, D. D. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080083 · Cited by 323
Self-citationRole of Vegf-Flt Receptor System in Normal and Tumor Angiogenesis
(1995) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60716-2 · Cited by 323
Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K. D., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 311
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Eskilsson, E., Røsland, G. V., Solecki, G., Wang, Q., Harter, P. N., Graziani, G., Verhaak, R. G. W., Winkler, F., Bjerkvig, R., & Miletic, H. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox191 · Cited by 310
Moscatello, D. K., Holgado-Madruga, M., Emlet, D. R., Montgomery, R. B., & Wong, A. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.200 · Cited by 305
Self-citationEGFR family: Structure physiology signalling and therapeutic targets †
Burgess, A. W. (2008) · Growth Factors · doi:10.1080/08977190802312844 · Cited by 288
Protein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 291
EGF receptor in neoplasia and metastasis
Khazaie, K., Schirrmacher, V., & Lichtner, R. B. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00665957 · Cited by 288
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., Herndon, J. E., Lally-Goss, D., McGehee-Norman, S., Paolino, A., Reardon, D. A., Friedman, A. H., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0124 · Cited by 287
Self-citationAldape, K. D., Ballman, K., Furth, A., Buckner, J. C., Giannini, C., Burger, P. C., Scheithauer, B. W., Jenkins, R. B., & James, C. D. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.7.700 · Cited by 278
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
Jaros, E., Perry, R., Adam, L., Kelly, P., Crawford, P., Kalbag, R., Mendelow, A., Sengupta, R., & Pearson, A. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.273 · Cited by 264
The complexity of targeting EGFR signalling in cancer: From expression to turnover
Sebastian, S., Settleman, J., Reshkin, S. J., Azzariti, A., Bellizzi, A., & Paradiso, A. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.001 · Cited by 260
Shimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
Lee, N. Y., Ermakova, S. P., Zvyagintseva, T. N., Kang, K. W., Dong, Z., & Choi, H. S. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.01.025 · Cited by 75
Liffers, K., Kolbe, K., Westphal, M., Lamszus, K., & Schulte, A. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0372-y · Cited by 41
Lee, N. Y., Ermakova, S. P., Choi, H., Kusaykin, M. I., Shevchenko, N. M., Zvyagintseva, T. N., & Choi, H. S. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20428 · Cited by 40
Metadata
- Authors
- Humphrey, P. A., Wong, A. J., Vogelstein, B., Zalutsky, M. R., Fuller, G. N., Archer, G. E., Friedman, H. S., Kwatra, M. M., Bigner, S. H., & Bigner, D. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1990-06
- Volume
- 87
- Issue
- 11
- Pages
- 4207-4211
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2043732412
- Cited by
- 382
- References
- 18
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.